Previous experimental studies using CK2 inhibitors have shown that tau phosphorylation, STAT1 phosphorylation, fast axonal transport (FAT), and GSK3 signaling are all associated with the role of CK2 in AD [14, 18, 65, 66]. The gene discussed is MAPT; the disease is Alzheimer disease.